Highlights
- Market Cap
- $885.16M
- Enterprise Value
- $902.75M
- EPS (TTM)
- -$3.18
- Total Revenue (TTM)
- $109.79M
- Gross Profit (TTM)
- $97.34M
- EBITDA (TTM)
- -$127.69M
- Year Range
- $3.42 - $30.00
- Target Price
- $35.60
- ROA (TTM)
- -76.57%
- ROE (TTM)
- 145.53%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in UroGen Pharma Ltd., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
UroGen Pharma Ltd. (URGN) has returned -23.23% so far this year and 62.57% over the past 12 months.
UroGen Pharma Ltd.
- 1D
- 5.76%
- 1M
- -17.14%
- YTD
- -23.23%
- 6M
- -9.87%
- 1Y
- 62.57%
- 3Y*
- 24.85%
- 5Y*
- -1.74%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since May 4, 2017, URGN's average daily return is +0.13%, while the average monthly return is +3.42%. At this rate, your investment would double in approximately 1.7 years.
Historically, 48% of months were positive and 52% were negative. The best month was Jun 2025 with a return of +223.1%, while the worst month was May 2025 at -63.6%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.
On a daily basis, URGN closed higher 47% of trading days. The best single day was Jul 27, 2023 with a return of +98.6%, while the worst single day was May 21, 2025 at -44.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -16.27% | 10.66% | -17.14% | -23.23% | |||||||||
| 2025 | 3.38% | -14.08% | 16.91% | 5.24% | -63.57% | 223.11% | 39.12% | 2.05% | 2.57% | 2.61% | 40.74% | -18.71% | 119.91% |
| 2024 | 4.67% | 16.75% | -18.17% | -7.87% | -3.76% | 26.17% | -1.97% | -15.44% | -8.70% | -3.46% | 3.59% | -16.14% | -29.00% |
| 2023 | 17.14% | -0.87% | -10.29% | 25.43% | -14.58% | 4.55% | 109.28% | -19.30% | -19.85% | -19.99% | 17.66% | 13.72% | 69.11% |
| 2022 | -18.82% | -22.28% | 45.17% | -18.94% | -24.65% | 53.95% | -4.27% | -4.97% | 11.68% | 42.43% | -27.68% | 3.50% | -6.73% |
| 2021 | 22.48% | -13.68% | 2.26% | -0.15% | -9.41% | -13.34% | 1.51% | 13.68% | -4.54% | 2.26% | -29.71% | -21.34% | -47.23% |
Benchmark Metrics
UroGen Pharma Ltd. has an annualized alpha of 20.67%, beta of 1.03, and R² of 0.06 versus S&P 500 Index. Calculated based on daily prices since May 05, 2017.
- This stock participated in 147.85% of S&P 500 Index downside but only 119.22% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.06 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 20.67%
- Beta
- 1.03
- R²
- 0.06
- Upside Capture
- 119.22%
- Downside Capture
- 147.85%
Return for Risk
Risk / Return Rank
URGN ranks 66 for risk / return — better than 66% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for UroGen Pharma Ltd. (URGN) and compare them to a chosen benchmark (S&P 500 Index).
| URGN | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.55 | 0.90 | -0.34 |
Sortino ratioReturn per unit of downside risk | 1.64 | 1.39 | +0.25 |
Omega ratioGain probability vs. loss probability | 1.24 | 1.21 | +0.03 |
Calmar ratioReturn relative to maximum drawdown | 0.91 | 1.40 | -0.49 |
Martin ratioReturn relative to average drawdown | 2.56 | 6.61 | -4.05 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore URGN risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the UroGen Pharma Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the UroGen Pharma Ltd. was 93.98%, occurring on May 27, 2025. The portfolio has not yet recovered.
The current UroGen Pharma Ltd. drawdown is 72.48%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -93.98% | May 21, 2018 | 1764 | May 27, 2025 | — | — | — |
| -20.07% | May 31, 2017 | 12 | Jun 15, 2017 | 7 | Jun 26, 2017 | 19 |
| -18.48% | Jan 26, 2018 | 7 | Feb 5, 2018 | 19 | Mar 5, 2018 | 26 |
| -16.63% | Sep 15, 2017 | 26 | Oct 20, 2017 | 9 | Nov 2, 2017 | 35 |
| -15.97% | Mar 15, 2018 | 12 | Apr 2, 2018 | 1 | Apr 3, 2018 | 13 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of UroGen Pharma Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how UroGen Pharma Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for URGN relative to other companies in the Biotechnology industry. Currently, URGN has a P/S ratio of 7.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |